Company: TXG
Filing Date: 2025-11-14
Form Type: 8-K
Source: 0001628280-25-052154
Chunk: 0

Company: 10x Genomics, Inc.
Filing Date: 2025-11-14
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

After more than eight years of exemplary service, on November 12, 2025 Eric S. Whitaker announced his intention to retire as Chief Legal Officer of 10x Genomics, Inc. (the “ Company”) effective January 1, 2026. Mr. Whitaker will remain an employee of the Company with reduced compensation and assume the position of Strategic Counsel, continuing to provide advice and counsel to the Company in connection with ongoing legal matters.

Dr. Randy Wu, who currently serves as the Company’s Vice President, Intellectual Property and Litigation, has been appointed to succeed Mr. Whitaker as General Counsel and Secretary of the Company effective January 1, 2026. Dr. Wu joined the Company in August 2016 after working as an attorney at Orrick, Herrington & Sutcliffe LLP. Dr. Wu holds a Ph. D. in Biophysics from the University of California, San Francisco, a J. D. from Stanford Law School and an A. B. in Chemistry from Harvard University.

Serge Saxonov, Co-Founder and Chief Executive Officer of the Company, said “ Eric has been an extraordinary partner to me and to 10x over the past eight years. From our IPO to navigating complex legal challenges, his leadership, judgment and integrity have helped shape who we are as a company. Beyond his many professional accomplishments, Eric has been a trusted counselor and a steady hand through every major milestone in our journey. I’m deeply grateful for all he’s contributed, and that he’ll continue to be part of 10x as an advisor.”

Saxonov continued, “ I’m thrilled to have Randy stepping into the role of General Counsel and Secretary. Randy has been with 10x for nearly a decade and knows our company, our mission and our people inside and out. He’s been integral to many of our biggest milestones and brings deep experience, sound judgment and a calm, practical approach that our teams trust and respect. I’m excited to see him take on this new role and continue building on the strong foundation he’s helped create.”

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  10x Genomics, Inc.                            
  By